Surveyor Capital

Founded 2008

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 84
Average round size
info
The average size of a deal this fund participated in
$111M
Portfolio companies 76
Rounds per year 6.46
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.10
Exits 35
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

Surveyor Capital appeared to be the VC, which was created in 2008.

Among the various public portfolio startups of the fund, we may underline Allogene Therapeutics, Annexon Biosciences, Oncorus The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Health Diagnostics, Pharmaceutical.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Surveyor Capital, startups are often financed by Skyline Ventures, SV Health Investors, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Alexandria Venture Investments, Samsara BioCapital. In the next rounds fund is usually obtained by Roche Venture Fund.

The top amount of exits for fund were in 2019. The top activity for fund was in 2019. This Surveyor Capital works on 11 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 50 - 100 millions dollars.

The overall number of key employees were 3.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ACELYRIN

Biopharma
Biotechnology
Health Care
$250M16 Nov 2021 Los Angeles, California, United States

Attralus

Biopharma
Biotechnology
Health Care
Medical
$116M08 Sep 2021 San Francisco, California, United States

Vigil Neuroscience

Biotechnology
$90M18 Aug 2021 Cambridge, Massachusetts, United States

Zentera Therapeutics

Biotechnology
Pharmaceutical
$75M04 Aug 2021 Shanghai, Shanghai, China

Turnstone Biologics

Biotechnology
Innovation Management
Therapeutics
$80M14 Jul 2021 San Francisco, California, United States

Nimbus Therapeutics

Alternative Medicine
Biotechnology
Health Care
Therapeutics
$105M13 Jul 2021 Cambridge, Massachusetts, United States

Point Biopharma

Biopharma
Biotechnology
Therapeutics
$165M01 Jul 2021 Indianapolis, Indiana, United States

NiKang Therapeutics

Biotechnology
Health Care
Medical
$200M26 May 2021 Wilmington, Delaware, United States

Larimar Therapeutics

Biotechnology
Medical
Therapeutics
$95M21 May 2021 Lower Merion Township, Pennsylvania, United States
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Surveyor Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: